AIM ImmunoTech Inc.
AIMAIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Drugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Ampligen
Chronic Fatigue Syndrome
Alferon LDO
Severe Acute Respiratory Syndrome
Rintatolimod
Post COVID-19 Condition
poly I-poly C12U
HIV Seropositivity
SARS-CoV-2 (LVRNA009) 50μg group
SARS-CoV-2
AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
Asthma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ampligen | Phase 3 | Chronic Fatigue Syndrome | - | - |
Alferon LDO | Phase 2 | Severe Acute Respiratory Syndrome | - | - |
Rintatolimod | Phase 2 | Post COVID-19 Condition | - | - |
poly I-poly C12U | Phase 2 | HIV Seropositivity | - | - |
SARS-CoV-2 (LVRNA009) 50μg group | Phase 2 | SARS-CoV-2 | - | - |
AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide | Phase 2 | Asthma | - | - |